Incidence and prevalence of Systemic Sclerosis (SSc) in Poland – differences between rural and urban regions
More details
Hide details
Department of Social Medicine and Public Health, Medical University of Warsaw, Poland
National Institute of Public Health – National Institute of Hygiene, Poland
University of Humanities and Economics in Lodz, Poland
Institute of Rural Health, Lublin, Poland
Corresponding author
Krzysztof Kanecki   

Department of Social Medicine and Public Health, Medical University of Warsaw, Poland
Ann Agric Environ Med. 2017;24(2):240-244
Systemic sclerosis (SSc) is a rare and potentially severe connective tissue disease, characterized by skin fibrosis and involvement of internal organs. Because of its rarity and heterogeneous clinical presentation, reliable epidemiological studies on SSc have been particularly difficult to carry out.

The purpose of this study was to present SSc epidemiology among hospitalized patients in Poland.

Material and Methods:
The analysis was based on population-based administrative data, taken from a Polish hospital morbidity study carried out by the National Institute of Public Health between January 2008 – December 2012.

Analyzed data covered 9,049 hospitalization records. The final sample comprised 3,653 patients with first-time hospitalizations for SSc. The average age of the sample was 53 years (SD 16.2; range 0–91 years); 84% of patients were female and 16% male. Based on hospitalization registers, the average SSc incidence was estimated to be 1.9/100,000 per year and peak age of incidence was 55 years. The point prevalence was estimated to be 9.4/100,000 at the end of 2012. SSc was more common in females, with F:M ratio ranging from 6.2:1–4.6:1 depending on the year. Analysis of hospitalization trends revealed that overall numbers of SSc hospitalizations increased, while first-time hospitalizations decreased between 2008–2012. Clusters of higher incidence were observed in more rural regions vs. urban regions.

Estimated incidence of SSc in Poland was comparable to reported incidence in other European countries. Analysis of demographic factors and reports of clusters of higher incidence may suggest the existence of environmental risk factors for the development of SSc. These observations may require further research

Simeon-Aznar CP, Fonollosa-Pla V, Tolosa-Vilella C, Espinosa-Garriga G, Ramos-Casals M, Campillo-Grau M, et al. Registry of the Spanish network for systemic sclerosis: clinical pattern according to cutaneous subsets and immunological status. Semin Arthritis Rheum. 2012; 41(6): 789–800,
Marie I, Gehanno JF, Bubenheim M, Duval-Modeste AB, Joly P, Dominique S, et al. Prospective study to evaluate the association between systemic sclerosis and occupational exposure and review of the literature. Autoimmun Rev. 2014; 13(2): 151–6,
Marie I, Menard JF, Duval-Modeste AB, Joly P, Dominique S, Bravard P, et al. Association of occupational exposure with features of systemic sclerosis. J Am Acad Dermatol. 2015; 72(3): 456–64,
Mayes MD, Lacey JV, Jr., Beebe-Dimmer J, Gillespie BW, Cooper B, Laing TJ, et al. Prevalence, incidence, survival, and disease characteristics of systemic sclerosis in a large US population. Arthritis Rheum. 2003; 48(8): 2246–55, 10.1002/art.11073.
Mayes MD. Scleroderma epidemiology. Rheum Dis Clin North Am. 2003; 29(2): 239–54.
Bernatsky S, Joseph L, Pineau CA, Belisle P, Hudson M, Clarke AE. Scleroderma prevalence: demographic variations in a population-based sample. Arthritis Rheum. 2009; 61(3): 400–4,
Barnabe C, Joseph L, Belisle P, Labrecque J, Edworthy S, Barr SG, et al. Prevalence of systemic lupus erythematosus and systemic sclerosis in the First Nations population of Alberta, Canada. Arthritis Care Res (Hoboken). 2012; 64(1): 138–43,
Le Guern V, Mahr A, Mouthon L, Jeanneret D, Carzon M, Guillevin L. Prevalence of systemic sclerosis in a French multi-ethnic county. Rheumatology (Oxford). 2004; 43(9): 1129–37,
Hoffmann-Vold AM, Midtvedt O, Molberg O, Garen T, Gran JT. Prevalence of systemic sclerosis in south-east Norway. Rheumatology (Oxford). 2012; 51(9): 1600–5,
Andréasson K, Saxne T, Bergknut C, Hesselstrand R, Englund M. Prevalence and incidence of systemic sclerosis in southern Sweden: population-based data with case ascertainment using the 1980 ARA criteria and the proposed ACR-EULAR classification criteria. Ann Rheum Dis. 2014; 73(10): 1788–92,
Chifflot H, Fautrel B, Sordet C, Chatelus E, Sibilia J. Incidence and prevalence of systemic sclerosis: a systematic literature review. SeminArthritis Rheum. 2008; 37(4): 223–35,
Arias-Nunez MC, Llorca J, Vazquez-Rodriguez TR, Gomez-Acebo I, Miranda-Filloy JA, Martin J, et al. Systemic sclerosis in northwestern Spain: a 19-year epidemiologic study. Medicine (Baltimore). 2008; 87(5): 272–80,
Barnes J, Mayes MD. Epidemiology of systemic sclerosis: incidence, prevalence, survival, risk factors, malignancy, and environmental triggers. Curr Opin Rheumatol. 2012; 24(2): 165–70,
Magnant J, Diot E. [Systemic sclerosis: epidemiology and environmental factors]. Presse Med. 2006; 35(12 Pt 2): 1894–901. French.
Simeón CP, Armadans L, Fonollosa V, Solans R, Selva A, Villar M, et al. Mortality and prognostic factors in Spanish patients with systemic sclerosis. Rheumatol. 2003; 42: 71–5.
Al-Dhaher FF, Pope JE, Ouimet JM. Determinants of morbidity and mortality of systemic sclerosis in Canada. Semin Arthritis Rheum. 2010; 39: 269–77.
Ranque B, Mouthon L. Geoepidemiology of systemic sclerosis. Autoimmun Rev. 2010; 9(5): A311–8,
Alba MA, Velasco C, Simeon CP, Fonollosa V, Trapiella L, Egurbide MV, et al. Early- versus late-onset systemic sclerosis: differences in clinical presentation and outcome in 1037 patients. Medicine (Baltimore). 2014; 93(2): 73–81,
Manno RL, Wigley FM, Gelber AC, Hummers LK. Late-age onset systemic sclerosis. J Rheumatol. 2011; 38(7): 1317–25,
Nagaraja V, McMahan ZH, Getzug T, Khanna D. Management of gastrointestinal involvement in scleroderma. Curr Treatm Opt Rheumatol. 2015; 1: 82–105.
Khanna D, Hays RD, Maranian P, Seibold JR, Impens A, Mayes MD, et al. Reliability and validity of the University of California, Los Angeles Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument. Arthritis Rheum. 2009; 61: 1257–63.
Scalapino K, Arkachaisri T, Lucas M, Fertig N, Helfrich DJ, Londino AV Jr, et al. Childhood onset systemic sclerosis: classification, clinical and serologic features, and survival in comparison with adult onset disease. J Rheumatol. 2006; 33(5): 1004–13,
Aoyama K, Nagai Y, Endo Y, Ishikawa O. Juvenile systemic sclerosis: report of three cases and review of Japanese published work. J Dermatol. 2007; 34(9): 658–61,
Central Statistical Office of Poland. [cited 1014 Oct 13]. Available from:
World Health Organization Regional Office for Europe. [cited 2014 Oct 27]. Available from:
Journals System - logo
Scroll to top